BREAKING NEWS! iTeos Therapeutics closes $125 Million Series B2 Financing
iTeos Therapeutics, biotech company in our Walloon ecosystem, raised $125 million to support the clinical development of its two innovative cancer immunotherapy programs.
Biotech company iTeos Therapeutics announced Wednesday that it has closed a $125 million Series B2 financing.
Proceeds from the financing will support the Company’s continued growth and advance the clinical development of its two lead product candidates, EOS-850, a best-in-class adenosine A2A receptor antagonist and EOS-448, an ADCC-enabled anti-TIGIT antibody.
“We are very pleased to have the strong support of this leading class of investors who share our excitement for the highly innovative oncology therapies we have developed at iTeos,” said Michel Detheux, PhD, President and Chief Executive Officer at iTeos.